Literature DB >> 7828296

Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS).

P R Liebson1, G A Grandits, S Dianzumba, R J Prineas, R H Grimm, J D Neaton, J Stamler.   

Abstract

BACKGROUND: Increased left ventricular mass (LVM) by echocardiography is associated with increased risk of cardiovascular disease. Thus, it is of interest to compare the effects of both pharmacological and nonpharmacological approaches to the treatment of hypertension on reduction of LVM. METHODS AND
RESULTS: Changes in LV structure were assessed by M-mode echocardiograms in a double-blind, placebo-controlled clinical trial of 844 mild hypertensive participants randomized to nutritional-hygienic (NH) intervention plus placebo or NH plus one of five classes of antihypertensive agents: (1) diuretic (chlorthalidone), (2) beta-blocker (acebutolol), (3) alpha-antagonist (doxazosin mesylate), (4) calcium antagonist (amlodipine maleate), or (5) angiotensin-converting enzyme inhibitor (enalapril maleate). Echocardiograms were performed at baseline, at 3 months, and annually for 4 years. Changes in blood pressure averaged 16/12 mm Hg in the active treatment groups and 9/9 mm Hg in the NH only group. All groups showed significant decreases (10% to 15%) in LVM from baseline that appeared at 3 months and continued for 48 months. The chlorthalidone group experienced the greatest decrease at each follow-up visit (average decrease, 34 g), although the differences from other groups were modest (average decrease among 5 other groups, 24 to 27 g). Participants randomized to NH intervention only had mean changes in LVM similar to those in the participants randomized to NH intervention plus pharmacological treatment. The greatest difference between groups was seen at 12 months, with mean decreases ranging from 35 g (chlorthalidone group) to 17 g (acebutolol group) (P = .001 comparing all groups). Within-group analysis showed that changes in weight, urinary sodium excretion, and systolic BP were moderately correlated with changes in LVM, being statistically significant in most analyses.
CONCLUSIONS: NH intervention with emphasis on weight loss and reduction of dietary sodium is as effective as NH intervention plus pharmacological treatment in reducing echocardiographically determined LVM, despite a smaller decrease in blood pressure in the NH intervention only group. A possible exception is that the addition of diuretic (chlorthalidone) may have a modest additional effect on reducing LVM.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7828296     DOI: 10.1161/01.cir.91.3.698

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  46 in total

Review 1.  Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

Authors:  D J Sheridan; M P Kingsbury; N A Flores
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

Review 2.  Nonhypertensive cardiac effects of a high salt diet.

Authors:  Gang Hu; Qing Qiao; Jaakko Tuomilehto
Journal:  Curr Hypertens Rep       Date:  2002-02       Impact factor: 5.369

3.  Left ventricular hypertrophy: unresolved issues.

Authors:  J A Schoenberger
Journal:  Curr Hypertens Rep       Date:  1999-08       Impact factor: 5.369

Review 4.  Epidemiology of risk factors for hypertension: implications for prevention and therapy.

Authors:  M Kornitzer; M Dramaix; G De Backer
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 5.  Regression of left ventricular hypertrophy is a key goal of hypertension management.

Authors:  Rubin Zhang; Judy Crump; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

6.  Stopping the cardiovascular disease continuum: Focus on prevention.

Authors:  Steven G Chrysant
Journal:  World J Cardiol       Date:  2010-03-26

7.  Effect of telmisartan on the regression of the left ventricular hypertrophy in the patients of essential hypertension.

Authors:  Kumar Haraprasad Misra; Mangala Charana Das; Y Roja Ramani
Journal:  J Clin Diagn Res       Date:  2013-07-01

Review 8.  Management of hypertension in patients with left ventricular hypertrophy.

Authors:  Cesare Cuspidi; Carla Sala; Alberto Zanchetti
Journal:  Curr Hypertens Rep       Date:  2007-12       Impact factor: 5.369

Review 9.  Role of echocardiography in primary care medicine. Controversies in hypertension, atrial fibrillation, stroke, and endocarditis.

Authors:  T M Amidon; T M Chou; L L Kee; E Foster
Journal:  West J Med       Date:  1996-03

10.  Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).

Authors:  Elsayed Z Soliman; Walter T Ambrosius; William C Cushman; Zhu-Ming Zhang; Jeffrey T Bates; Javier A Neyra; Thaddeus Y Carson; Leonardo Tamariz; Lama Ghazi; Monique E Cho; Brian P Shapiro; Jiang He; Lawrence J Fine; Cora E Lewis
Journal:  Circulation       Date:  2017-05-16       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.